X
X
Total 667546 Results
| Label | Description | ILX | Version | Created CID | Modified Time | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Conditioned place preference paradigm | A behavioral conditioning paradigm where the animal is presented with a positive stimulus (e.g., food or the effects of a drug of abuse) paired with placement in a distinct environment containing various cues (e.g., tactile, visual, and/or olfactory). When later tested in the normal state, measures of the preference for the compartments previously associated with the positive stimulus, e.g., approaches or amount of time spent in the compartment, serves as an indicator of preference and a measure of reward learning. This paradigm is commonly used in animal studies to evaluate preferences for environmental stimuli that have been associated with a positive or negative reward. The technique is often used to determine the addiction potential of drugs. (adapted from Wikipedia) | ILX:0102461 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Conditioning paradigm | ILX:0102462 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Conductance | Measure of how easily electricity flows along a certain path through an electrical element. The SI derived unit of conductance is the siemens. | ILX:0102463 | 5 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Conduction | The transmission of an entity through a medium. | ILX:0102464 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Conduction failure | A failure of the action potential to propagate down the axon. | ILX:0102465 | 5 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Conductivity | A physical quality inhering in a bearer by virtue of the bearer's ability to transmit of an entity through a medium. | ILX:0102466 | 6 | scicrunch | 08/24/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Conenzyme A | A coenzyme containing pantothenic acid, adenosine 3-phosphate 5-pyrophosphate, and cysteamine; involved in the transfer of acyl groups, notably in transacetylations (NCI Thesaurus). | ILX:0102467 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Conference proceeding | ILX:0102468 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Confidentiality Code | Confidentiality Constraints on the Requested Procedure by the party filling the order. | ILX:0102469 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Confidentiality Constraint on Patient Data Description | Special indication to the modality operator about confidentiality of patient information (e.g., that he should not use the patients name where other patients are present). | ILX:0102470 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Configuration | ILX:0102471 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Confocal imaging protocol | ILX:0102472 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Confocal microscope | A microscope that is used to increase micrograph contrast and/or reconstruct three-dimensional images by using a spatial pinhole to eliminate out-of-focus light in specimens that are thicker than the focal plane. | ILX:0102473 | 4 | scicrunch | 06/12/2021 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Congenital Myasthenic Syndrome | A heterogeneous group of disorders characterized by a congenital defect in neuromuscular transmission at the NEUROMUSCULAR JUNCTION. This includes presynaptic, synaptic, and postsynaptic disorders (that are not of autoimmune origin). The majority of these diseases are caused by mutations of various subunits of the nicotinic acetylcholine receptor ( RECEPTORS, NICOTINIC) on the postsynaptic surface of the junction (MeSH). | ILX:0102474 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Congenital retinoschisis | ILX:0102475 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Congested | ILX:0102476 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Conical | A convex 3-D shape that resembles a cone (a 3-D shape with a round cross section that tapers). | ILX:0102477 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Conical papilla | ILX:0102478 | 6 | scicrunch | 06/23/2020 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| CONICET | The CONICET is the leading organization dedicated to the promotion of science and technology in Argentina. It operates in four major areas* agricultural sciences, engineering and materials * life sciences and health * natural sciences * Social Sciences and HumanitiesThe National Scientific and Technical Research Council (Spanish: Consejo Nacional de Investigaciones Científicas y Técnicas, CONICET) is an Argentine government agency which directs and co-ordinates most of the scientific and technical research done in universities and institutes. It was established on 5 February 1958 by a decree of the national government. Its first director was Medicine Nobel Prize Bernardo A. Houssay.Nowadays, it is governed by a board completely independent from the federal government. It funds scientific research in three basic ways. First, CONICET gives grants for collective work to research teams of well-recognized scientists of every discipline (including social sciences and humanities). Secondly, it has a roll of 6,500 researches and 2,500 technicians as employees in different categories, from investigador asistente" to "investigador principal". And thirdly | ILX:0102479 | 0 | scicrunch | 01/01/1970 | scicrunch | 01/01/1970 | 0 | NeuroLex | troy sincomb | |
| Conivaptan | Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). Pharmacology: Conivaptan is a nonpeptide, dual antagonist of arginine vasopressin (AVP) V1A and V2 receptors. The level of AVP in circulating blood is critical for the regulation of water and electrolyte balance and is usually elevated in both euvolemic and hypervolemic hyponatremia. The AVP effect is mediated through V2 receptors, which are functionally coupled to aquaporin channels in the apical membrane of the collecting ducts of the kidney. These receptors help to maintain plasma osmolality within the normal range. The predominant pharmacodynamic effect of conivaptan in the treatment of hyponatremia is through its V2 antagonism of AVP in the renal collecting ducts, an effect that results in aquaresis, or excretion of free water. The pharmacodynamic effects of conivaptan include increased free water excretion (i.e., effective water clearance (EWC)) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality. Mechanism of action: Conivaptan is a dual AVP antagonist with nanomolar affinity for human V1A and V2 receptors in vitro. This antagonism occurs in the renal collecting ducts, resulting in aquaresis, or excretion of free water. Drug type: Approved. Investigational. Small Molecule. Drug category: Aquaresis promoters | ILX:0102480 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
About
Base community for the SciCrunch.org infrastructure
Contact Us
X